Breast Cancer | Specialty

A Background on TNBC and Management

April 29th 2019

Dr. Tolaney on Presence of PIK3CA and ESR1 Mutations in MONARCH 2 Trial in Breast Cancer

April 26th 2019

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the presence of PIK3CA mutations and ESR1 mutations in patients with breast cancer enrolled in the phase III MONARCH 2 trial.

Role of Liquid Biopsies Still Needs Refining in Breast Cancer

April 25th 2019

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

Dr. Newman on Health Disparities in Breast Cancer

April 25th 2019

Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.

Metastatic Cancer Is a Chronic Condition

April 23rd 2019

Advancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.

Atezolizumab Approval Sets Stage for Future Drug Development in TNBC

April 18th 2019

Mariana Chavez Mac Gregor, MD, MSc, discussex recent shifts in the treatment of patients with metastatic triple-negative breast cancer.

Dr. O'Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast Cancer

April 13th 2019

Joyce A. O’Shaughnessy, MD, co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, Texas Oncology, chair of The US Oncology Network, and 2016 Giant of Cancer Care® in Community Outreach, discusses the clinical implications of the TEXT and SOFT trials in premenopausal women with hormone receptor-positive breast cancer.

Highlighting Breakthroughs in Breast Cancer in Nashville

April 10th 2019

We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.

Olaparib Approved in Europe for BRCA+ Breast Cancer

April 10th 2019

The European Commission has approved olaparib (Lynparza) for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.

ACP Releases Breast Cancer Screening Guidance Statements for Asymptomatic, Average-Risk Women

April 9th 2019

For women at average risk for breast cancer who are between the ages of 40 and 49 years, clinicians should have a personalized approach on whether their patients should be screened with mammography prior to the age of 50.

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

April 5th 2019

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Breast Cancer Leaders Reflect on Progress

April 5th 2019

This year we are celebrating the 20th anniversary of our flagship publication OncologyLive. To mark the occasion, we are asking oncology leaders to reflect on the tremendous progress made in cancer research and practice over the past 2 decades.

FDA Approves Palbociclib for Male Patients With HR+/HER2- Breast Cancer

April 4th 2019

The FDA has expanded the approval of palbociclib capsules in combination with endocrine therapy for male patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.

Surgery Linked With Improved OS in HER2+ Advanced Breast Cancer

April 2nd 2019

Primary tumor surgery for patients with stage IV HER2-positive breast cancer is associated with an improvement in overall survival, according to results of a retrospective cohort review presented at the 2019 AACR Annual Meeting.

T-VEC Plus Chemo Hits High pCR Rate in TNBC

April 1st 2019

A majority of patients with large triple-negative breast tumors achieved pathologic complete response when treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy.

Implications for Systemic Therapy in Breast Cancer

March 29th 2019

Novel Therapies in TNBC: Real-World Experience

March 29th 2019

I-O + PARP Inhibition for Triple-Negative Breast Cancer

March 29th 2019

Checkpoint Inhibitors for Triple-Negative Breast Cancer

March 29th 2019

Adjuvant T-DM1 Therapy in HER2+ Breast Cancer

March 29th 2019